临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
APX-3330
中文名称:E3330抑制剂
CAS号:136164-66-4
分子式: C21H30O6 分子量: 378.46
产品形式: free base
研发状态: Completed
研发用途: Cancer
研究机构: Apexian Pharmaceuticals Inc.
研发日期: January 30 2018
研发阶段: Phase 1
APX-3330 (E3330) is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.
Minocycline (CL 59806) HCl
中文名称: 盐酸米诺环素
CAS号:13614-98-7
分子式: C23H27N3O7.HCl 分子量: 493.94
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Sickle Cell Disease; Cognitive Impairment; Cognitive Decline; Cognitive Change; Cognitive Dysfunction; Cognitive Deficit; Neuroinflammatory Response
研究机构: University of Cincinnati
研发日期: June 1 2024
研发阶段: Phase 1
Minocycline (CL 59806,Minocin) HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
M3541
CAS号:1360628-91-6
分子式: C23H17FN6O2 分子量: 428.42
产品形式: free base
研发状态: Terminated
研发用途: Solid Tumors
研究机构: EMD Serono Research & Development Institute Inc.; Merck KGaA Darmstadt Germany; EMD Serono
研发日期: September 6 2017
研发阶段: Phase 1
M3541 is a potent and selective inhibitor of ATM kinase activity with an IC50 value of 0.25 nM in cell-free assays. M3541 suppresses double-strand breaks (DSB) repair, clonogenic cancer cell growth and potentiates antitumor activity of ionizing radiation in cancer cell lines.
Anlotinib (AL3818) dihydrochloride
中文名称:安罗替尼盐酸盐
CAS号:1360460-82-7
分子式: C23H22FN3O3.2HCl 分子量: 480.36
产品形式: dihydrochloride
研发状态: Not yet recruiting
研发用途: Breast Cancer
研究机构: Fudan University
研发日期: April 1 2024
研发阶段: Phase 1
Anlotinib (AL3818) is a highly potent and selective VEGFR2 inhibitor with IC50 less than 1 nM. It has broad-spectrum antitumor potential in clinical trials. Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.
Fluzoparib (SHR-3162)
CAS号:1358715-18-0
分子式: C22H16F4N6O2 分子量: 472.40
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
研究机构: Fudan University
研发日期: March 1 2023
研发阶段: Phase 2
Fluzoparib (SHR3162, HS10160) is a potent Poly (ADP-ribose) polymerase (PARP) inhibitor that shows anti-tumor activity, with an IC50 of 1.46±0.72 nM for PARP1.
ON123300
中文名称:8-环戊基-7,8-二氢-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-7-氧代-吡啶并[2,3-D]嘧啶-6-甲腈
CAS号:1357470-29-1
分子式: C24H27N7O 分子量: 429.52
产品形式: free base
研发状态: Not yet recruiting
研发用途: Relapsed and/or Refractory Multiple Myeloma
研究机构: Adriana Rossi; Icahn School of Medicine at Mount Sinai
研发日期: June 3 2024
研发阶段: Phase 1 : Phase 2
ON123300 is a potent and multi-targeted kinase inhibitor with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM for CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), and Fyn, respectively.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
